Lakewood-Amedex Biotherapeutics Inc.
LABT evidence brief
What we can confirm
- Market Cap:
- $5.3M
What it means
What to watch
Prepared research question
What matters most for LABT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LABT
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a biotechnology company developing a novel class of antimicrobials, the Bisphosphocins, to address antibiotic-resistant infections, with its lead candidate Nu-3 targeting infected diabetic foot ulcers.
Key risk: Going concern doubt
Market Cap
$5.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a biotechnology company developing a novel class of antimicrobials, the Bisphosphocins, to address antibiotic-resistant infections, with its lead candidate Nu-3 targeting infected diabetic foot ulcers.
- Lead product candidate Nu-3 is a broad-spectrum Bisphosphocin antimicrobial for topical treatment of chronically infected diabetic foot ulcers; a first-in-human exploratory trial has been completed [sec_mda · as of 2026-09-18].
- The company holds 68 issued and 36 pending patent applications for its products and technologies as of April 2026 [sec_mda · as of 2026-05-22].
- Cash & equivalents were $2.6M as of 2026-06-30, with net income of -$3.8M and shareholders' equity of $4.3M [sec].
- The company's auditors have stated that recurring losses from operations raise substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-01].
- A Series C Convertible Preferred Stock financing generated net proceeds of approximately $6.8M, significantly improving liquidity during the six months ended June 30, 2026 [sec_mda · as of 2026-08-14].
What works
- The company has a novel Bisphosphocin class of antimicrobials that are designed to be broad-spectrum and less vulnerable to existing resistance mechanisms [sec_mda · as of 2026-09-18].
- A strong intellectual property portfolio with 68 issued and 36 pending patent applications as of April 2026 [sec_mda · as of 2026-05-22].
- The company successfully completed a first-in-human exploratory clinical trial for its lead candidate Nu-3 and plans to advance into Phase 2 studies [sec_mda · as of 2026-09-18].
- Recent financing (Series C Convertible Preferred Stock) improved liquidity, with working capital rising to approximately $4.2 million as of mid-2026 [sec_mda · as of 2026-08-14].
What to weigh
- The company has a history of recurring losses from operations, and its auditors have expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-01].
- Cash & equivalents were only $2.6M as of 2026-06-30, and the company expects expenses to increase significantly as it advances clinical development [sec].
- The company's continued operations depend on raising additional capital, with no assurance that financing will be available on acceptable terms [sec_mda · as of 2026-05-01].
- Nu-3 is still in early clinical stages (Phase 2a planned), and the company has no approved products or commercial revenue [sec_mda · as of 2026-09-18].
From the filings
Quoted directly from source documents.
Lead candidate Nu-3 is a broad-spectrum Bisphosphocin antimicrobial for infected diabetic foot ulcers.
“Our lead product candidate, Nu-3, is a broad-spectrum Bisphosphocin ® antimicrobial formulated for the topical treatment of chronically infected diabetic foot ulcers (iDFUs).”
SEC MD&A · September 18, 2026
The company's auditors raised substantial doubt about its ability to continue as a going concern.
“our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · May 1, 2026
Series C financing improved liquidity.
“The significant improvement in the Company's liquidity and financial position during the six months ended June 30, 2026 was primarily attributable to the completion of its Series C Convertible Preferred Stock financing, which generated net proceeds of approximately $6.8 million.”
SEC MD&A · August 14, 2026
The company holds a substantial patent portfolio.
“As of April 2026, we hold 68 issued and 36 pending patent applications for our products and technologies”
SEC MD&A · May 22, 2026
Risks & what to watch (4)›
Key risks
- Going concern doubt — Auditors stated recurring losses raise substantial doubt about ability to continue as a going concern [sec_mda · as of 2026-05-01].
- Cash runway limited — Cash & equivalents of $2.6M as of 2026-06-30, with expenses expected to rise significantly [sec].
- No approved products — Nu-3 is in early clinical stages; no commercial revenue and no guarantee of regulatory approval [sec_mda · as of 2026-09-18].
- Dependence on financing — Operations depend on raising additional capital with no assurance of acceptable terms [sec_mda · as of 2026-05-01].
What to watch
- Initiation and results of the planned Phase 2a safety and dose-response trial for Nu-3 [sec_mda · as of 2026-09-18].
- Ability to secure additional financing to support clinical development and operations [sec_mda · as of 2026-05-01].
- Progress of preclinical pipeline candidates Nu-8, Nu-10, and Nu-11 [sec_mda · as of 2026-09-18].
- Any updates on patent grants or regulatory milestones [sec_mda · as of 2026-05-22].
Sources: SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Lakewood-Amedex Biotherapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lakewood-Amedex Biotherapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Lakewood-Amedex Biotherapeutics Inc.?
Lakewood-Amedex Biotherapeutics Inc. (LABT) is a biotechnology company developing a novel class of antimicrobials, the Bisphosphocins, to address antibiotic-resistant infections, with its lead candidate Nu-3 targeting infected diabetic foot ulcers.
Who is the CEO of Lakewood-Amedex Biotherapeutics Inc.?
Dr. Kelvin Cooper Ph.D. is the chief executive officer of Lakewood-Amedex Biotherapeutics Inc. (LABT).
Where is Lakewood-Amedex Biotherapeutics Inc. headquartered?
Lakewood-Amedex Biotherapeutics Inc. (LABT) is headquartered in University Park, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.